CytoMed Therapeutics Income Statement

Financials in millions SGD. Fiscal year is January - December.

Millions SGD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.32	0.07	-	-	-
Revenue Growth (YoY)	366.74%	-	-	-	-
Cost of Revenue	0.07	0.02	-	-	-
Gross Profit	0.26	0.05	-	-	-
Selling, General & Admin	0.93	0.62	0.45	0.21	0.17
Depreciation & Amortization Expenses	0.23	0.12	0.1	0.11	0.1
Research & Development	2.22	1.91	1.59	1.52	1.09
Other Operating Expenses	0.99	0.21	1.41	0.01	0.36
Total Operating Expenses	4.37	2.87	3.56	1.85	1.72
Operating Income	-4.11	-2.81	-3.56	-1.85	-1.72
Interest Income	-0.01	0.01	-0.03	-0.03	-0.21
Interest Expense	-0.02	-0.02	-0.05	-0.13	-0.12
Other Non-Operating Income (Expense)	0.14	0.3	-0.49	-1.12	0
Total Non-Operating Income (Expense)	0.11	0.29	-0.58	-1.28	-0.33
Pretax Income	-4	-2.52	-4.13	-3.13	-2.05
Provision for Income Taxes	-	-	0	0	-
Net Income	-3.98	-2.52	-4.13	-3.13	-2.05
Minority Interest in Earnings	-0.02	-0.01	-0	-0	-0
Net Income to Common	-3.98	-2.52	-4.13	-3.13	-2.05
Shares Outstanding (Basic)	12	12	11	8	8
Shares Outstanding (Diluted)	12	12	11	8	8
Shares Change (YoY)	0.93%	8.56%	34.30%	-	34.21%
EPS (Basic)	-0.34	-0.22	-0.39	-0.40	-0.40
EPS (Diluted)	-0.34	-0.22	-0.39	-0.40	-0.40
Shares Outstanding	11.83	11.54	11.53	8.44	7.48
Free Cash Flow	-4.34	-4.11	-3.59	-1.87	-2.3
Free Cash Flow Per Share	-0.37	-0.36	-0.34	-0.24	-0.29
Gross Margin	79.04%	75.37%	-	-	-
Operating Margin	-1266.81%	-4047.22%	-	-	-
Profit Margin	-1231.97%	-3628.52%	-	-	-
FCF Margin	-1336.46%	-5913.81%	-	-	-
EBITDA	-3.71	-2.48	-3.18	-1.46	-1.39
EBITDA Margin	-1143.01%	-3564.69%	-	-	-
EBIT	-4.11	-2.81	-3.56	-1.85	-1.72
EBIT Margin	-1266.81%	-4047.22%	-	-	-
Effective Tax Rate	0.00%	0.00%	-0.02%	-0.05%	0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q